REGN

Regeneron Pharmaceuticals Inc
776.71
25.51 (3.40%)
Company Name Stock Ticker Symbol Market Type
Regeneron Pharmaceuticals Inc REGN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
25.51 3.4% 776.71 10:42:13
Open Price Low Price High Price Close Price Prev Close
763.52 758.6263 782.00 751.20
more quote information »

Recent News

Date Time Source Heading
2/02/20239:58IHNWFeaturedGoldshore Intersects 9.46 g/t Au over 7.45m in the Southwest Zone Widths of Mineralized System Expanded Significantly.
2/03/202307:07EDGARCurrent Report Filing (8-k)
2/03/202306:30GLOBERegeneron Reports Fourth Quarter and Full Year 2022..
1/31/202316:01GLOBERegeneron Announces Investor Conference Presentations
1/30/202316:12EDGARStatement of Changes in Beneficial Ownership (4)
1/30/202301:00GLOBEDupixent® (dupilumab) Approved by European Commission as the..
1/27/202300:59GLOBEDupixent® (dupilumab) Recommended for Expanded EU Approval..
1/24/202312:02PRNUSTop 40 High School Scientists Selected as Finalists in the..
1/24/202312:00GLOBETop 40 High School Scientists Selected as Finalists in the..
1/11/202312:10EDGARStatement of Ownership (sc 13g)
1/10/202316:04EDGARStatement of Changes in Beneficial Ownership (4)
1/09/202310:40DJNRegeneron Pharmaceuticals Down Over 8%, on Pace for Largest..
1/09/202308:50EDGARCurrent Report Filing (8-k)
1/06/202310:13DJN2seventy Bio, Regeneron in Amended Collaboration
1/05/202316:38EDGARStatement of Changes in Beneficial Ownership (4)
1/05/202316:23EDGARStatement of Changes in Beneficial Ownership (4)
1/05/202316:22EDGARStatement of Changes in Beneficial Ownership (4)
1/05/202316:22EDGARStatement of Changes in Beneficial Ownership (4)
1/05/202316:21EDGARStatement of Changes in Beneficial Ownership (4)
1/05/202316:20EDGARStatement of Changes in Beneficial Ownership (4)
1/05/202316:17EDGARStatement of Changes in Beneficial Ownership (4)
1/05/202316:16EDGARStatement of Changes in Beneficial Ownership (4)
1/05/202316:14EDGARStatement of Changes in Beneficial Ownership (4)
1/03/202316:01GLOBERegeneron to Report Fourth Quarter and Full Year 2022..
12/23/202208:30PRNUSLibtayo® (cemiplimab) Approved in Japan for Advanced or..
12/21/202217:29PRNUSPositive Dupixent® (dupilumab) Phase 3 Results in Adults and..
12/20/202217:45EDGARStatement of Changes in Beneficial Ownership (4)
12/20/202216:11EDGARStatement of Changes in Beneficial Ownership (4)
12/20/202216:08EDGARStatement of Changes in Beneficial Ownership (4)
12/20/202216:07EDGARStatement of Changes in Beneficial Ownership (4)
12/20/202216:07EDGARStatement of Changes in Beneficial Ownership (4)
12/20/202216:02EDGARCurrent Report Filing (8-k)
12/19/202216:01PRNUSRegeneron Announces Presentation at the 41st Annual J.P...
12/16/202208:23DJNRegeneron, Sanofi Get CHMP Backing for Dupixent in..
12/16/202207:29PRNUSDupixent® (dupilumab) Recommended for EU Approval by the..
12/15/202200:59PRNUSDupixent® (dupilumab) Approved by European Commission as the..
12/13/202216:14EDGARStatement of Changes in Beneficial Ownership (4)
12/13/202216:13EDGARStatement of Changes in Beneficial Ownership (4)
12/13/202216:13EDGARStatement of Changes in Beneficial Ownership (4)
12/13/202216:12EDGARStatement of Changes in Beneficial Ownership (4)
12/13/202216:11EDGARStatement of Changes in Beneficial Ownership (4)
12/13/202216:11EDGARStatement of Changes in Beneficial Ownership (4)
12/12/202217:30PRNUSOdronextamab (CD20xCD3) Demonstrates High and Durable..
12/12/202216:36EDGARStatement of Changes in Beneficial Ownership (4)
12/12/202216:35EDGARStatement of Changes in Beneficial Ownership (4)
12/12/202210:00PRNUSLinvoseltamab (BCMAxCD3) Initial Pivotal Phase 2 Data Show..
12/12/202207:30PRNUSRegeneron Named on Dow Jones Sustainability World Index for..
12/11/202210:30PRNUSPivotal Odronextamab (CD20xCD3) Phase 2 Data in Patients..
12/06/202223:30TRMNAnalysts Offer Insights on Healthcare Companies: Regeneron..
12/02/202216:08EDGARStatement of Changes in Beneficial Ownership (4)
12/02/202216:07EDGARStatement of Changes in Beneficial Ownership (4)